scispace - formally typeset
P

Philip A. Poole-Wilson

Researcher at National Institutes of Health

Publications -  443
Citations -  69648

Philip A. Poole-Wilson is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Heart failure & Heart disease. The author has an hindex of 105, co-authored 443 publications receiving 66861 citations. Previous affiliations of Philip A. Poole-Wilson include Harefield Hospital & St George's Hospital.

Papers
More filters
Journal ArticleDOI

Skeletal Muscle Function and Its Relation to Exercise Tolerance in Chronic Heart Failure

TL;DR: In patients with chronic HF, quadriceps maximal isometric strength is reduced and muscular atrophy becomes a major determinant of exercise capacity and is an independent predictor of peak absolute VO2.
Journal ArticleDOI

Coronary artery disease as the cause of incident heart failure in the population

TL;DR: Coronary artery disease is the cause of 52% (95% CI 43-61%) of incident heart failure in the general population under 75 years and clinical assessment without angiography under-estimates the proportion of patients with coronary artery disease, and fails to identify those patients who may benefit from revascularization.
Journal ArticleDOI

Endothelium-independent relaxation of rabbit coronary artery by 17β-oestradiol in vitro

TL;DR: It is suggested that a calcium antagonistic property may be involved in the mechanism of rabbit coronary arterial relaxation by 17β‐oestradiol by an endothelium‐independent mechanism in vitro.
Journal ArticleDOI

Elevated soluble CD14 receptors and altered cytokines in chronic heart failure.

TL;DR: Patients with high soluble CD14 levels have markedly increased plasma levels of TNF-alpha, soluble TNF receptors 1 and 2, and intracellular adhesion molecule-1, supporting this hypothesis that in patients with chronic heart failure mesenteric venous congestion leads to increased bowel permeability, bacterial translocation, and thereby endotoxin release.
Journal ArticleDOI

5-year outcome of an interventional strategy in non-ST-elevation acute coronary syndrome: the British Heart Foundation RITA 3 randomised trial

TL;DR: In patients with non-ST-elevation acute coronary syndrome, a routine invasive strategy leads to long-term reduction in risk of death or non-fatal myocardial infarction, and this benefit is mainly in high-risk patients.